Febrile neutropenia cyclophosphamide

In a study, 627 patients with breast cancer were given either doxorubicin 50 mg/m with docetaxel 75 mg/m, or doxorubicin 60 mg/m with cyclophosphamide 600 mg/m postoperatively for 4 courses to assess disease-free survival at 5 years. The study was terminated prematurely because of the high risk of life-threatening complications in those given doxorubicin with docetaxel (2 deaths associated with drug toxicity and one case of perforated peritonitis in patients with febrile neutropenia). The incidence of febrile neutropenia was 40.8% and 7.1% in the doxorubicin-docetaxel and doxorubicin-cyclophosphamide groups, respectively. ... 

---